Akari Therapeutics to Present at Webull Financial Corporate Connect Webinar Series

Akari Therapeutics will present at the Webull Financial Corporate Connect Webinar Series on August 19, 2025. CEO Abizer Gaslightwala will discuss the company's advancements in Antibody Drug Conjugates for cancer treatment. The virtual event runs from August 19-21, 2025, focusing on biotechnology and medical technology innovations. Akari Therapeutics is known for its novel payload, PH1, which targets the Trop2 receptor on cancer cells.

Akari Therapeutics, a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event. The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025 [1].

The presentation will highlight Akari Therapeutics' advancements in developing novel payload antibody drug conjugates (ADCs). The company's first novel payload, PH1, is a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing modulator has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity [2].

Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls [2].

The Webull Financial Corporate Connect Webinar Series is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. The event will provide an opportunity for investors and financial professionals to learn more about Akari Therapeutics' innovative approach to cancer treatment and the potential of their lead candidate, AKTX-101 [1].

References:
[1] https://www.stocktitan.net/news/AKTX/akari-therapeutics-to-present-at-the-webull-financial-corporate-7uel0y6gzv3d.html
[2] https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-present-webull-financial-corporate-connect